-
Mashup Score: 0
Recently, a man aged 50 years came to my office. He had received surgery for a right-sided non-functional adrenocortical carcinoma measuring 11 cm in diameter and had been referred to discuss adjuvant treatment. Based on adrenal histology findings, he had a European Network for the Study of Adrenal Tumors (ENS@T) tumour stage II, which means no lymph node metastases, and a [18F]fluorodeoxyglucose-PET scan had ruled out distant metastasis.1 Fortunately, he had undergone oncological tumour resection resulting in complete resection.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 5
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 2
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 2
Recently, a man aged 50 years came to my office. He had received surgery for a right-sided non-functional adrenocortical carcinoma measuring 11 cm in diameter and had been referred to discuss adjuvant treatment. Based on adrenal histology findings, he had a European Network for the Study of Adrenal Tumors (ENS@T) tumour stage II, which means no lymph node metastases, and a [18F]fluorodeoxyglucose-PET scan had ruled out distant metastasis.1 Fortunately, he had undergone oncological tumour resection resulting in complete resection.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Encouraging Trends in Outcomes in Patients With Adrenocortical Carcinoma at a Multidisciplinary Referral Center - 1 year(s) ago
Study shows that a multidisciplinary, person-centered approach is needed to improve outcomes
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Encouraging Trends in Outcomes in Patients With Adrenocortical Carcinoma at a Multidisciplinary Referral Center - 2 year(s) ago
Study shows that a multidisciplinary, person-centered approach is needed to improve outcomes
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Adrenocortical Carcinoma Outcomes Are Improving - 2 year(s) ago
Study looks at trends in disease burden and clinical outcomes
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Pitfalls and progress in adrenocortical carcinoma diagnosis: the utility of a multidisciplinary approach, immunohistochemistry and genomics - 2 year(s) ago
Summary Adrenocortical carcinoma is a rare disease with poor prognosis whose clinical heterogeneity can at times present a challenge to accurate and timely diagnosis. We present the case of a patient who presented with extensive pulmonary lesions, mediastinal and hilar lymphadenopathy and an adrenal mass in whom the oncological diagnosis was initially uncertain. Through the use of…
Source: EDM Case ReportsCategories: Endocrinology, Latest HeadlinesTweet-
Don't miss this new case exploring the pitfalls & progress in #adrenocortical carcinoma diagnosis. Ray Wang et al., discuss the utility of a multidisciplinary approach, immunohistochemistry & genomics. https://t.co/MikiffZmsL Authors are members of @AUDiabetesSoc & @EndoSocAus https://t.co/SGrSvR0DQh
-
-
Mashup Score: 0Study evaluates efficacy of adjuvant mitotane in patients with adrenocortical carcinoma - 2 year(s) ago
A recent study suggests that patients with adrenocortical carcinoma at low-intermediate risk of recurrence do not derive significant benefit from postoperative adjuvant mitotane treatment.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
Martin Reincke comments: Good news for patients with #adrenocortical carcinoma from the #ADIUVO trial https://t.co/LDK290bhAr #adrenal #ACC